Who is sponsoring NCT03941886?

NCT03941886 is sponsored by Chiu Yee Liona Poon.

What drugs are being tested in NCT03941886?

Interventions in NCT03941886: Low-dose aspirin in women with high risk of preeclampsia.

What condition does NCT03941886 study?

NCT03941886 studies Pre-Eclampsia.

Is NCT03941886 still recruiting?

NCT03941886 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT03941886: FORECAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST)

Completed NA Last updated 29 November 2023

What this trial tests

NA trial testing Low-dose aspirin in women with high risk of preeclampsia in Pre-Eclampsia in 42,454 participants. Completed in 15 August 2023.

Timeline

31 July 2019

Primary endpoint
15 June 2023

15 August 2023

Quick facts

Lead sponsor	Chiu Yee Liona Poon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	42,454
Start date	31 July 2019
Primary completion	15 June 2023
Estimated completion	15 August 2023
Sites	19 locations across Hong Kong, Japan, Malaysia, Taiwan, Indonesia, Vietnam, Philippines, Thailand

Drugs / interventions tested

Low-dose aspirin in women with high risk of preeclampsia

Conditions studied

Pre-Eclampsia — all drugs for Pre-Eclampsia →

Sponsor

Chiu Yee Liona Poon

Who can join

18 and older, female only, with Pre-Eclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This implementation study aims to evaluate the efficacy, acceptability, and safety of first-trimester screening and prevention for preterm-preeclampsia. It is a multicenter stepped wedge cluster randomized trial including maternity / diagnostic units from ten regions in Asia. The study involves a period where no intervention will take place at all recruiting units, and then at regular intervals, one cluster will be randomized to transit from non-intervention group to intervention group in which first-trimester screening for preterm-preeclampsia by the Bayes based method followed by the commencement of low-dose aspirin in high-risk women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pre-Eclampsia

Currently open trials in the same condition.

NCT07245056 — Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia · NA · recruiting
NCT07187596 — Mortality Outcome of Controlled Hypertension · active not recruiting
NCT06893510 — Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia · NA · recruiting
NCT06122220 — Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia. · NA · recruiting
NCT06779916 — Autophagy/Apoptosis Balance in Placental Vascular Pathologies · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03941886 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiu Yee Liona Poon
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing